Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.40
CBST's Cash to Debt is ranked higher than
52% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. CBST: 0.40 )
CBST' s 10-Year Cash to Debt Range
Min: 0.19   Max: 35.27
Current: 0.4

0.19
35.27
Equity to Asset 0.48
CBST's Equity to Asset is ranked higher than
62% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CBST: 0.48 )
CBST' s 10-Year Equity to Asset Range
Min: -0.48   Max: 0.95
Current: 0.48

-0.48
0.95
Interest Coverage 0.70
CBST's Interest Coverage is ranked lower than
53% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBST: 0.70 )
CBST' s 10-Year Interest Coverage Range
Min: 0.31   Max: 7.41
Current: 0.7

0.31
7.41
F-Score: 5
Z-Score: 3.61
M-Score: -2.50
WACC vs ROIC
2.02%
4.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 10.54
CBST's Operating margin (%) is ranked higher than
89% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. CBST: 10.54 )
CBST' s 10-Year Operating margin (%) Range
Min: -2763   Max: 29.79
Current: 10.54

-2763
29.79
Net-margin (%) 5.59
CBST's Net-margin (%) is ranked higher than
87% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. CBST: 5.59 )
CBST' s 10-Year Net-margin (%) Range
Min: -3094.81   Max: 29.49
Current: 5.59

-3094.81
29.49
ROE (%) 4.49
CBST's ROE (%) is ranked higher than
88% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. CBST: 4.49 )
CBST' s 10-Year ROE (%) Range
Min: -5818.4   Max: 69.13
Current: 4.49

-5818.4
69.13
ROA (%) 2.10
CBST's ROA (%) is ranked higher than
89% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. CBST: 2.10 )
CBST' s 10-Year ROA (%) Range
Min: -73.44   Max: 20.9
Current: 2.1

-73.44
20.9
ROC (Joel Greenblatt) (%) 13.93
CBST's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. CBST: 13.93 )
CBST' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -300.09   Max: 141.6
Current: 13.93

-300.09
141.6
Revenue Growth (3Y)(%) 15.00
CBST's Revenue Growth (3Y)(%) is ranked higher than
86% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. CBST: 15.00 )
CBST' s 10-Year Revenue Growth (3Y)(%) Range
Min: -41.3   Max: 209.9
Current: 15

-41.3
209.9
EBITDA Growth (3Y)(%) -43.60
CBST's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. CBST: -43.60 )
CBST' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -46.9   Max: 93.6
Current: -43.6

-46.9
93.6
» CBST's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CBST Guru Trades in Q1 2014

Lee Ainslie 1,739,818 sh (New)
Jim Simons 189,091 sh (+50.17%)
Murray Stahl 24,000 sh (unchged)
Vanguard Health Care Fund 1,323,142 sh (unchged)
Stanley Druckenmiller Sold Out
Paul Tudor Jones Sold Out
Andreas Halvorsen Sold Out
RS Investment Management 504,845 sh (-5.81%)
Chuck Royce 219,900 sh (-28.56%)
Pioneer Investments 368,542 sh (-28.57%)
George Soros 50,000 sh (-65.40%)
Steven Cohen 3,082 sh (-89.81%)
» More
Q2 2014

CBST Guru Trades in Q2 2014

Ken Fisher 36,450 sh (New)
Vanguard Health Care Fund 1,467,542 sh (+10.91%)
Murray Stahl 24,000 sh (unchged)
Steven Cohen 394,200 sh (unchged)
George Soros Sold Out
Lee Ainslie Sold Out
Pioneer Investments 358,881 sh (-2.62%)
Chuck Royce 211,600 sh (-3.77%)
RS Investment Management 390,565 sh (-22.64%)
Jim Simons 47,420 sh (-74.92%)
» More
Q3 2014

CBST Guru Trades in Q3 2014

Vanguard Health Care Fund 1,977,342 sh (+34.74%)
Murray Stahl 24,000 sh (unchged)
Pioneer Investments 338,388 sh (unchged)
RS Investment Management Sold Out
Jim Simons Sold Out
Ken Fisher 34,775 sh (-4.60%)
Chuck Royce 197,980 sh (-6.44%)
Steven Cohen 340,200 sh (-13.70%)
» More
Q4 2014

CBST Guru Trades in Q4 2014

Eric Mindich 1,904,073 sh (New)
Paul Singer 539,000 sh (New)
Prem Watsa 20,200 sh (New)
George Soros 120,000 sh (New)
Jean-Marie Eveillard 20,000 sh (New)
Mario Gabelli 236,700 sh (New)
Jean-Marie Eveillard 200 sh (unchged)
Vanguard Health Care Fund 1,977,342 sh (unchged)
Steven Cohen Sold Out
Pioneer Investments Sold Out
Chuck Royce Sold Out
Murray Stahl 19,000 sh (-20.83%)
Ken Fisher 2,150 sh (-93.82%)
» More
» Details

Insider Trades

Latest Guru Trades with CBST

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Cubist Pharmaceuticals Inc

Prem Watsa's Stock Buys and Sells of Q4
“Canadian Warren Buffett (Trades, Portfolio)” Prem Watsa (Trades, Portfolio) bought sparingly in the fourth quarter, as he saw “a disconnect between the financial markets and the underlying economic fundamentals,” he said in his third-quarter conference call. Read more...
Gabelli's Q4 Picks Include Acquisition Targets
Mario Gabelli (Trades, Portfolio) founded GAMCO Investors in 1977, which runs a variety of mutual and closed-end funds. The Gabelli Asset Fund manages $3.6 billion in assets as of the fourth quarter and is rated 4 stars by Morningstar. Read more...
Mario Gabelli's Top 5 New Stock Buys of Q4
GAMCO Investors, Mario Gabelli (Trades, Portfolio)’s, purchased 32 stocks in the fourth quarter, for 3% turnover in its portfolio of 861 stocks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 126.00
CBST's P/E(ttm) is ranked higher than
88% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 126.00 )
CBST' s 10-Year P/E(ttm) Range
Min: 7.41   Max: 3802.11
Current: 126

7.41
3802.11
Forward P/E 24.94
CBST's Forward P/E is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 24.94 )
N/A
PE(NRI) 135.90
CBST's PE(NRI) is ranked higher than
89% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 135.90 )
CBST' s 10-Year PE(NRI) Range
Min: 7.56   Max: 244.68
Current: 135.9

7.56
244.68
P/B 5.01
CBST's P/B is ranked higher than
72% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. CBST: 5.01 )
CBST' s 10-Year P/B Range
Min: 1.85   Max: 81.28
Current: 5.01

1.85
81.28
P/S 7.23
CBST's P/S is ranked higher than
81% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. CBST: 7.23 )
CBST' s 10-Year P/S Range
Min: 1.98   Max: 36.83
Current: 7.23

1.98
36.83
PFCF 68.42
CBST's PFCF is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 68.42 )
CBST' s 10-Year PFCF Range
Min: 8.06   Max: 277.85
Current: 68.42

8.06
277.85
POCF 55.70
CBST's POCF is ranked higher than
91% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 55.70 )
CBST' s 10-Year POCF Range
Min: 7.09   Max: 2357
Current: 55.7

7.09
2357
EV-to-EBIT 70.99
CBST's EV-to-EBIT is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 70.99 )
CBST' s 10-Year EV-to-EBIT Range
Min: -341   Max: 265.1
Current: 70.99

-341
265.1
Shiller P/E 79.98
CBST's Shiller P/E is ranked higher than
94% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 79.98 )
CBST' s 10-Year Shiller P/E Range
Min: 22.92   Max: 105.2
Current: 79.98

22.92
105.2
Current Ratio 3.54
CBST's Current Ratio is ranked higher than
70% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. CBST: 3.54 )
CBST' s 10-Year Current Ratio Range
Min: 0.9   Max: 14.48
Current: 3.54

0.9
14.48
Quick Ratio 3.29
CBST's Quick Ratio is ranked higher than
70% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CBST: 3.29 )
CBST' s 10-Year Quick Ratio Range
Min: 0.81   Max: 14.48
Current: 3.29

0.81
14.48
Days Inventory 64.74
CBST's Days Inventory is ranked higher than
93% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 64.74 )
CBST' s 10-Year Days Inventory Range
Min: 60.95   Max: 848.31
Current: 64.74

60.95
848.31
Days Sales Outstanding 36.08
CBST's Days Sales Outstanding is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. CBST: 36.08 )
CBST' s 10-Year Days Sales Outstanding Range
Min: 13.52   Max: 128.67
Current: 36.08

13.52
128.67

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) 1.40
CBST's Earnings Yield (Greenblatt) is ranked higher than
89% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CBST: 1.40 )
CBST' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 23.3
Current: 1.4

0.4
23.3
Forward Rate of Return (Yacktman) -14.01
CBST's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 15.81 vs. CBST: -14.01 )
CBST' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -41.9   Max: 106.1
Current: -14.01

-41.9
106.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CU6.Germany,
Cubist Pharmaceuticals, Inc., was incorporated as a Delaware corporation in 1992. It is a biopharmaceutical company that provides research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Its products and product candidates are used, or are being developed to be used, in hospitals and other acute care settings, including home infusion and hospital outpatient clinics. Its currently marketed products include CUBICIN, DIFICID, and DIFICID. CUBICIN is a once-daily, bactericidal, I.V. antibiotic with activity against certain Gram-positive organisms, including MRSA. CUBICIN is approved in more than 50 countries including the U.S., EU, and Japan. DIFICID is a macrolide antibiotic for the treatment of CDAD. ENTEREG is an oral, peripherally-acting mu opioid receptor antagonist. The Company currently relies on a global network of third party contract manufacturers to manufacture its starting materials, active pharmaceutical ingredients, or APIs, and finished drug products for commercial sale. Its competitors include Abbott, Shionogi & Co., Ltd., Pfizer, Inc., King Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., ViroPharma Incorporated, among others. The Company's current and contemplated activities, and the products and processes that result from such activities, are subject to substantial government regulation.
» More Articles for CBST

Headlines

Articles On GuruFocus.com
Prem Watsa Buys 2 and Sells 1 Stock in Fourth Quarter Feb 17 2015 
Mario Gabelli's Top 5 New Stock Buys of Q4 Feb 06 2015 
Gabelli's Q4 Picks Include Acquisition Targets Feb 06 2015 
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
Michael Price’s Top Sells – 11 Gurus Exit SFD Nov 19 2013 
Magic Formula Formulator Joel Greenblatt’s Top 5 New Stock Picks Feb 14 2013 
5 Healthcare Stocks to Consider in 2012 Mar 21 2012 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceutical - Acutely Aware May 09 2010 

More From Other Websites
Farallon Capital Starts New Position in Cubist Pharmaceuticals Mar 20 2015
Tetraphase looks to double its cash with stock offering Mar 10 2015
Layoffs at Cubist come amid a steady flow of senior execs out of Merck Mar 06 2015
Elliott Management exits position in Covidien Mar 04 2015
Elliott Management starts new position in Cubist Pharmaceuticals Mar 02 2015
Prem Watsa's Stock Buys and Sells of Q4 Feb 17 2015
Dana Holding Set to Join the S&P MidCap 400 Jan 20 2015
Cubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market Jan 13 2015
Cubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market Jan 13 2015
Teixobactin And iChip Promise Hope Against Antibiotic Resistance Jan 08 2015
Cramer's Mad Dash: Pharma movers Dec 24 2014
Approval of new antibiotic by Cubist to help in $100 trillion global fight Dec 22 2014
FDA Approves Second Cubist Antibiotic Of 2014 Dec 19 2014
Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated... Dec 19 2014
Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated... Dec 19 2014
FDA approves Cubists' drug for antibiotic-resistant bacteria Dec 19 2014
Merck Begins Tender Offer to Acquire Cubist Dec 19 2014
$100 trillion Superbugs threat Dec 18 2014
Tetraphase Jumps As 'Superbug' Drug Scores In Trial Dec 18 2014
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist... Dec 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK